CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC announced today the appointment of Jeffrey Trigilio as the company’s Chief Financial Officer. In addition to his primary financial responsibilities, Jeff will play an important role across many facets of the business, including business development, project management and investor relations.
“We are fortunate to have someone of Jeff’s caliber join Cullinan at this stage of the company’s development,” stated Owen Hughes, CEO of Cullinan Oncology. “Jeff’s vast experience across a number of disciplines within the healthcare ecosystem will serve us well as we look to scale the company and progress several candidates into clinical development over the coming months.”
Jeff has served in a variety of financial roles in his career, most recently as the Chief Financial Officer of Amylyx, a biopharmaceutical company developing a small molecule therapeutic for ALS and other neurological diseases, and Vice President of Finance at BlueRock Therapeutics, an engineered cell therapy company that was acquired by Bayer AG.
Previously, Jeff held roles of increasing responsibility at Alexion Pharmaceuticals, a global biotechnology company focused on rare diseases, in corporate strategy and finance, including serving as Executive Director, Strategic Decision Analysis. At Alexion, he worked closely with executive leadership on long range planning, mergers and acquisitions, manufacturing, pricing and reimbursement and tax planning throughout a significant growth period during which the company expanded into multiple products and therapeutic areas.
Jeff added, “Cullinan is advancing a robust, diversified pipeline of both targeted and immuno-oncology programs. The track record of its leadership team, founders and investors make this an exciting opportunity.”
Jeff started his career in healthcare equity capital markets and investment banking at Credit Suisse and RBC Capital Markets. He holds a B.S. from Cornell University and an MBA from Columbia Business School.
About Cullinan Oncology, LLC
Cullinan Oncology was formed to develop a diversified portfolio of single asset oncology opportunities through both internal and external means and to do so in a unique, cost-efficient model that leverages a central management team and shared services model to drive speed and efficiency. For additional information, please visit www.cullinanoncology.com.
